A5091949242- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Immunotherapy and Immune Responses
- Immunodeficiency and Autoimmune Disorders
- Systemic Sclerosis and Related Diseases
- COVID-19 epidemiological studies
Chulabhorn Hospital
2023
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) increases mortality rates in older adults and those with comorbidities. Individuals certain comorbidities may have a poor immune response require early booster vaccines. We aimed to assess the after two doses of ChAdOx1 nCoV-19 vaccine, at 84-day intervals, participants following comorbidities; diabetes mellitus; obesity; cardiovascular disease; chronic kidney rheumatological cirrhosis; hematological malignancy; or solid...
The present study aimed to the immunogenicity of ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies.This prospective cohort hematology evaluate their antibody levels against receptor-binding domain severe acute respiratory syndrome coronavirus 2 spike protein and seroconversion rates following two doses vaccine. Between June July 2021, we enrolled 61 included 44 our analysis. Antibody were assessed 8 4 weeks after first second injections, respectively, compared those a healthy...